Claims
- 1. A method of increasing the mutation rate of a virus, comprising administering the compound to a virally infected cell, wherein the compound has the structure:
- 2. The method according to claim 1, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 3. The method according to claim 2, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 4. The method according to claim 1, said compound having the structure:
- 5. The method according to claim 3, wherein said halogen is fluoro.
- 6. The method according to claim 1, wherein in said genomic nucleic acid encoding the virus, said compound replaces a first natural occurring nucleotide having a first complementary nucleotide wherein said compound complements a second nucleotide which is other than the first nucleotide, thereby inducing the virus to mutate.
- 7. The method according to claim 1, wherein said genomic nucleic acid is an RNA copy of the genomic nucleic acid.
- 8. The method according to claim 1, wherein said genomic nucleic acid is a DNA copy of the genomic nucleic acid.
- 9. The method according to claim 1, wherein the virus is a retrovirus or a flavivirus.
- 10. The method according to claim 1, wherein the virus is a pestivirus.
- 11. The method according to claim 1, wherein the cell is in cell culture.
- 12. The method according to claim 1, wherein the cell is in an animal.
- 13. The method according to claim 1, wherein the cell is a human cell.
- 14. The method according to claim 1, wherein increasing the mutation rate of the virus produces a progressive loss of viability of the virus.
- 15. The method according to claim 1, comprising administration of more than one compound to the virally infected cell.
- 16. The method according to claim 1, wherein the virus is an RNA virus selected from the group consisting of hepatitis C, coronavirus, influenza, respiratory syncytial virus, BVDV, and dengue fever virus.
- 17. The method according to claim 1, wherein the virus is a DNA virus.
- 18. A method of increasing the mutation rate of a virus, comprising administering the compound to a virally infected cell, wherein the compound has the structure:
- 19. The method according to claim 18, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 20. The method according to claim 19, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 21. The method according to claim 20, wherein said halogen is fluoro.
- 22. The method according to claim 18, wherein in said genomic nucleic acid encoding the virus, said compound replaces a first natural occurring nucleotide having a first complementary nucleotide wherein said compound complements a second nucleotide which is other than the first nucleotide, thereby inducing the virus to mutate.
- 23. The method according to claim 18, wherein said genomic nucleic acid is an RNA copy of the genomic nucleic acid.
- 24. The method according to claim 18, wherein said genomic nucleic acid is a DNA copy of the genomic nucleic acid.
- 25. The method according to claim 18, wherein the virus is a retrovirus or a flavivirus.
- 26. The method according to claim 18, wherein the virus is a pestivirus.
- 27. The method according to claim 18, wherein the cell is in cell culture.
- 28. The method according to claim 18, wherein the cell is in an animal.
- 29. The method according to claim 18, wherein the cell is a human cell.
- 30. The method according to claim 18, wherein increasing the mutation rate of the virus produces a progressive loss of viability of the virus.
- 31. The method according to claim 18, comprising administration of more than one compound to the virally infected cell.
- 32. The method according to claim 18, wherein the virus is an RNA virus selected from the group consisting of hepatitis C, coronavirus, influenza, respiratory syncytial virus, BVDV, and dengue fever virus.
- 33. The method according to claim 18, wherein the virus is a DNA virus.
- 34. A method of increasing the mutation rate of a virus, comprising administering the compound to a virally infected cell, wherein the compound has the structure:
- 35. The method according to claim 34, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 36. The method according to claim 35, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 37. The method according to claim 36, wherein said halogen is fluoro.
- 38. The method according to claim 34, wherein in said genomic nucleic acid encoding the virus, said compound replaces a first natural occurring nucleotide having a first complementary nucleotide wherein said compound complements a second nucleotide which is other than the first nucleotide, thereby inducing the virus to mutate.
- 39. The method according to claim 34, wherein said genomic nucleic acid is an RNA copy of the genomic nucleic acid.
- 40. The method according to claim 34, wherein said genomic nucleic acid is a DNA copy of the genomic nucleic acid.
- 41. The method according to claim 34, wherein the virus is a retrovirus or a flavivirus.
- 42. The method according to claim 34, wherein the virus is a pestivirus.
- 43. The method according to claim 34, wherein the cell is in cell culture.
- 44. The method according to claim 34, wherein the cell is in an animal.
- 45. The method according to claim 34, wherein the cell is a human cell.
- 46. The method according to claim 34, wherein increasing the mutation rate of the virus produces a progressive loss of viability of the virus.
- 47. The method according to claim 34, comprising administration of more than one compound to the virally infected cell.
- 48. The method according to claim 34, wherein the virus is an RNA virus selected from the group consisting of hepatitis C, coronavirus, influenza, respiratory syncytial virus, BVDV, and dengue fever virus.
- 49. The method according to claim 34, wherein the virus is a DNA virus.
- 50. A method of increasing the mutation rate of a virus, comprising administering the compound to a virally infected cell, wherein the compound has the structure:
- 51. The method according to claim 50, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 52. The method according to claim 51, said compound having the structure:
- 53. The method according to claim 51, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 54. The method according to claim 53, wherein said halogen is fluoro.
- 55. The method according to claim 50, wherein in said genomic nucleic acid encoding the virus, said compound replaces a first natural occurring nucleotide having a first complementary nucleotide wherein said compound complements a second nucleotide which is other than the first nucleotide, thereby inducing the virus to mutate.
- 56. The method according to claim 50, wherein said genomic nucleic acid is an RNA copy of the genomic nucleic acid.
- 57. The method according to claim 50, wherein said genomic nucleic acid is a DNA copy of the genomic nucleic acid.
- 58. The method according to claim 50, wherein the virus is a retrovirus or a flavivirus.
- 59. The method according to claim 50, wherein the virus is a pestivirus.
- 60. The method according to claim 50, wherein the cell is in cell culture.
- 61. The method according to claim 50, wherein the cell is in an animal.
- 62. The method according to claim 50, wherein the cell is a human cell.
- 63. The method according to claim 50, wherein increasing the mutation rate of the virus produces a progressive loss of viability of the virus.
- 64. The method according to claim 50, comprising administration of more than one compound to the virally infected cell.
- 65. The method according to claim 50, wherein the virus is an RNA virus selected from the group consisting of hepatitis C, coronavirus, influenza, respiratory syncytial virus, BVDV, and dengue fever virus.
- 66. The method according to claim 50, wherein the virus is a DNA virus.
- 67. A compound having the structure:
- 68. The compound according to claim 67, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 69. The compound according to claim 67, said compound having the structure:
- 70. The compound according to claim 68, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 71. The compound according to claim 70, wherein said halogen is fluoro.
- 72. A compound having the structure:
- 73. The compound according to claim 72, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 74. The compound according to claim 72, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 75. The compound according to claim 74, wherein said halogen is fluoro.
- 76. A compound having the structure:
- 77. The compound according to claim 76, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 78. The compound according to claim 77, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 79. The compound according to claim 78, wherein said halogen is fluoro.
- 80. A compound having the structure:
- 81. The compound according to claim 80, wherein said sugar residue is substituted or unsubstituted ribose or deoxyribose.
- 82. The compound according to claim 80 having the structure:
- 83. The compound according to claim 81, wherein said substituted or unsubstituted ribose or deoxyribose is a member selected from the group of:
- 84. The compound according to claim 83, wherein said halogen is fluoro.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Ser. No. 60/314,728, filed Aug. 24, 2001, herein incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60314728 |
Aug 2001 |
US |